...
首页> 外文期刊>Clinics >Autopsy-proven causes of death in lungs of patients immunocompromised by secondary interstitial pneumonia
【24h】

Autopsy-proven causes of death in lungs of patients immunocompromised by secondary interstitial pneumonia

机译:继发性间质性肺炎免疫功能低下的尸检证明死因

获取原文

摘要

PURPOSE: To present the more frequent associations found in autopsies of immunocompromised patients who developed secondary interstitial pneumonia as well as the risk of death (odds ratio) in having specific secondary interstitial pneumonia according to the cause of immunocompromise. METHOD: From January 1994 to March 2004, 17,000 autopsies were performed at Hospital das Clínicas, S?o Paulo University Medical School. After examining the pathology report review, we selected 558 of these autopsies (3.28%) from patients aged 15 years or more with primary underlying diseases who developed radiologically diffuse infiltrates of the lung during their hospital course and died after secondary interstitial pneumonia (bronchopneumonia, lobar pneumonia, interstitial pneumonia, diffuse alveolar damage, pulmonary recurrence of underlying disease, drug-induced lung disease, cardiogenic pulmonary edema, or pulmonary embolism). Histology slides were reviewed by experienced pathologists to confirm or not the presence of secondary interstitial pneumonia. Statistical analysis included the Fisher exact test to verify any association between histopathology and the cause of immunocompromise; a logistic regression was used to predict the risk of death for specific histological findings for each of the independent variables in the model. RESULTS: Secondary interstitial pneumonia was histologically represented by diffuse interstitial pneumonitis ranging from mild nonspecific findings (n = 213) to a pattern of diffuse alveolar damage (n = 273). The principal causes of immunocompromise in patients with diffuse alveolar damage were sepsis (136 cases), neoplasia (113 cases), diabetes mellitus (37 cases), and transplantation (48 cases). A high risk of death by pulmonary edema was found for patients with carcinoma of colon. Similarly, in patients with lung cancer or cachexia, A high risk of death by bronchopneumonia (OR = 3.6; OR = 2.6, respectively) was found. Pulmonary thromboembolism was associated with an appreciable risk of death (OR = 2.4) in patients with arterial hypertension. The risk of death was also high in patients presenting hepatic cancer (OR = 2.5) or steroid therapy (OR = 2.4) who developed pulmonary hemorrhage as the histological pattern of secondary interstitial pneumonia . The risk of death by lung metastasis was also elevated (OR = 1.6) for patients that were immunosuppressed after radiotherapy. CONCLUSION: Patients with secondary immunosuppression who developed secondary interstitial pneumonia during treatment in hospital should be evaluated to avoid death by diffuse alveolar damage, pulmonary edema, bronchopneumonia, lung hemorrhage, pulmonary thromboembolism, or lung metastasis. The high-risk patients are those immunosuppressed by hematologic disease; those under steroid treatment; or those with colon or hepatic carcinoma, cachexia, or arterial hypertension.
机译:目的:介绍在继发于间质性肺炎的免疫功能低下患者的尸检中发现的更频繁的关联,以及根据免疫受损的原因而患有特定继发性间质性肺炎的死亡风险(比值比)。方法:从1994年1月至2004年3月,在圣保罗大学医学院的dasClínicas医院进行了17,000次尸检。在检查了病理报告后,我们从15岁或以上的原发性基础疾病患者中选择了558例尸检(3.28%),这些患者在住院过程中发生了放射性弥漫性肺部浸润并在继发性间质性肺炎(支气管肺炎,大叶肺炎,间质性肺炎,弥漫性肺泡损伤,基础疾病的肺复发,药物性肺病,心源性肺水肿或肺栓塞)。由经验丰富的病理学家对组织学切片进行审查,以确认是否存在继发性间质性肺炎。统计分析包括Fisher精确检验,以验证组织病理学与免疫功能低下的原因之间是否存在关联;对于模型中每个独立变量的特定组织学发现,使用逻辑回归来预测死亡风险。结果:继发性间质性肺炎在组织学上表现为弥漫性间质性肺炎,范围从轻度非特异性发现(n = 213)到弥漫性肺泡损伤(n = 273)。弥漫性肺泡损伤患者免疫功能低下的主要原因是败血症(136例),瘤形成(113例),糖尿病(37例)和移植(48例)。对于结肠癌患者,发现因肺水肿导致高死亡风险。同样,在患有肺癌或恶病质的患者中,发现支气管肺炎的高死亡风险(分别为OR = 3.6; OR = 2.6)。肺动脉血栓栓塞与明显的死亡风险(OR = 2.4)相关。表现为继发性间质性肺炎的组织学类型为肺出血的肝癌(OR = 2.5)或类固醇治疗(OR = 2.4)的患者死亡风险也很高。放疗后被免疫抑制的患者因肺转移而死亡的风险也升高了(OR = 1.6)。结论:在医院治疗期间发生继发性间质性肺炎的继发性免疫抑制患者应进行评估,以避免因弥漫性肺泡损害,肺水肿,支气管肺炎,肺出血,肺血栓栓塞或肺转移而死亡。高危患者是血液系统免疫抑制的患者;接受类固醇治疗的人;或患有结肠癌或肝癌,恶病质或动脉高血压的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号